Podcast: Aetna Letter Sparks Controversy

Summary: After announcing an exit from the majority of the healthcare exchanges in which it currently operates, Aetna is receiving criticism over a letter it had previously sent to the Department of Justice (DOJ). In it, Aetna’s CEO stated that if the merger between his organization and Humana was blocked, the company would have to leave the exchange business. Aetna claims to have left due to financial concerns and profitability issues with the program setup, but some wonder if the letter was meant as a veiled threat. Experts point out that if the latter is true, the attempt was misguided – the DOJ typically does not consider political pressures when examining anti-trust cases and is attempting to block the merger regardless of the letter’s intent.

Hear the full podcast from Marketplace here.

Fearing Zika, FDA Asks Two Florida Counties to Halt Blood Donations

After travel and sexual transmissions were ruled out for four Zika cases in Florida counties of Miami-Dade and Broward, fears of infected mosquitos in the United States are mounting. Because the virus does not present symptoms in many cases, it is possible that more people are infected – and may have donated blood after being bitten. The FDA has issued a warning that blood collections in the counties should not resume until they are able to properly test the blood and screen donors; they also recommend that neighboring and other at-risk counties consider taking the same actions.

Read NPR's article on it here.

Is your PBM proven? WE ARE. Visit Script Care's website to learn more about who WE ARE.

www.scriptcare.com/WeAre.cfm

Sanders, Other Lawmakers Urge FDA Approval of Generic Crestor

Two months ago, AstraZeneca gained approval for the use of Crestor in children suffering from homozygous familial hypercholesterolemia (HoFH) and, under the Orphan Drug Act (ODA), the drug then qualified for extended market exclusivity for the treatment of this new condition. With the impending loss of patent protection for Crestor’s common use in adults, AstraZeneca has filed a lawsuit accusing the FDA of illegally interpreting a federal law that will allow generic medications to exclude indications for HoFH on their labels. Without the ruling, generic manufacturers would be required to include HoFH dosing and instructions on their labels, therefore violating the exclusivity granted by the ODA and extending AstraZeneca’s market hold. Bernie Sanders, along with several other lawmakers, are petitioning the FDA to approve the generics and offer a lower cost alternative to consumers.

Read the Stat News article on it here.

[Podcast from 2 Docs Talk] Direct-To-Consumer Marketing - Letting the Fox Guard The Henhouse

Summary: Direct-to-consumer drug marketing has, historically, been a controversial topic. In 2002, Merck spent $160 million on a marketing campaign for the new pain medication, Vioxx. Later, the drug was found to increase the risk of stroke and heart attacks and was being used, largely, by individuals who were well-suited for alternative drugs (like ibuprofen). In addition to the increased potential for misuse, many ad claims are misleading for consumers: A reported “significant” increase in length of life for patients on a treatment for lung cancer is actually three months. As pressure builds to regulate, or even halt, these advertising practices, the pharmaceutical industry has a proposed solution. They recommend giving the FDA approval rights for all prescription drug ads prior to their release, funded by manufacturers through a per ad ‘user fee.’ This approach is already used for drug approvals, with manufacturers funding over half of the FDA’s budget; prior to the implementation of these fees in 1993, drug company investment accounted for less than 10% of funds received by the FDA. Opponents of the measure are concerned how the impact of additional pharma industry funding will jeopardize the ultimate efficacy of the FDA’s practices.

Here the podcast from 2 Docs Talk here.

'Cross Protection' Occurs Between Bacterial Strains

Scientists recently discovered a mutually beneficial relationship occurring between bacterial strains: cross protection. In a new study, researchers grew two types of E. coli, each resistant to a different antibiotic, in the same test tube. The environment also contained the two antibiotics to which the strains were resistant. Instead of being eliminated, both bacteria deactivated “their” antibiotic, providing protection for the other strain. While not occurring in this study, experts suspect that, over time, this stable environment could lead to the exchange of resistance genes – making both strains of bacteria resistant to both antibiotics.

Listen to Scientific American's podcast about it here.

Is your PBM competitive? WE ARE. Visit Script Care's website to learn more about who WE ARE.

Learn more at www.scriptcare.com/WeAre.cfm